Journal
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
Volume 15, Issue 5-6, Pages 344-350Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/21678421.2014.884592
Keywords
ALS; CSF biomarker; multicentre sample-collection approach with centralized sample processing; cystatin C; tau; MCP-1; amyloid-beta
Categories
Funding
- European Commission
- Thierry Latran Foundation
- BMBF (FTLD consortium)
- Stiftung Baden-Wurttemberg
- France, Agence Nationale de la Recherche
- Germany, Bundesministerium fur Bildung und Forschung
- Ireland, Health Research Board
- Italy, Ministero della Salute
- Netherlands, The Netherlands Organisation for Health Research and Development
- Poland, Narodowe Centrum Badan i Rozwoju
- Portugal, Fundacao a Ciencia e a Tecnologia
- Spain, Ministerio de Ciencia e Innovacion
- Switzerland, Schweizerischer Nationalfonds zur Forderung der wissenschaftlichen Forschung
- Turkey, Tubitak
- United Kingdom, Medical Research Council
- Medical Research Council [MR/K000039/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0512-10082] Funding Source: researchfish
- MRC [MR/K000039/1] Funding Source: UKRI
Ask authors/readers for more resources
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that mainly causes degeneration of the upper and lower motor neurons, ultimately leading to paralysis and death within three to five years after first symptoms. The pathological mechanisms leading to ALS are still not completely understood. Several biomarker candidates have been proposed in cerebrospinal fluid (CSF). However, none of these has successfully translated into clinical routine. Part of the reason for this failure to translate may relate to differences across laboratories. For this reason, several of the most commonly used ALS biomarker candidates were evaluated on clinically well-defined ALS samples from six European centres in a multicentre sample-collection approach with centralized sample processing. Results showed that phosphorylated neurofilament heavy chain differentiated between ALS and control cases in all centres. We therefore propose that measurement of phosphorylated neurofilaments in CSF is the most promising candidate for translation into the clinical setting and might serve as a benchmark for other biomarker candidates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available